PA1-21796

antibody from Invitrogen Antibodies

Targeting: VEGFA VEGF, VEGF-A, VPF

Antibody data

Submit

Validation data

Product number: PA1-21796 - Provider product page
Provider: Invitrogen Antibodies
Product name: VEGF Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Recombinant full-length protein
Description: Recommended positive controls: Tumor cells in hemangiosarcomas.
Concentration: 0.2 mg/mL

VEGFA protein structure - PA1-21796 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 (a) Tangential longitudinal section of rat's femur stained with anti-VEGF. Osteoblasts expressing VEGF (black arrow). (b) Immunoreactive score (IRS) of VEGF in each group. Each bar represents the mean IRS +- SEM of the two rats observed in at least two different visual fields. * P =0.05, ** p < 0.05, *** p < 0.001 with Kruskal Wallis.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 7 ( a ), ( d ) Immunohistochemistry staining images showing expression of eNOS in cardiac muscle x100 (inset: x400) and thoracic aorta x400 respectively of control and tramadol treated mice. Arrows show the specific staining for the antibody. ( b ), ( e ) Relative quantification of immunohistochemistry staining for eNOS in cardiac muscle and thoracic aorta, respectively of both groups, n = 10. Data are expressed as means +- SEM, *p < 0.05 for control versus tramadol. ( c ), ( f ) Relative quantitative expression of mRNA levels of eNOS in cardiac muscle and thoracic aorta respectively of control and tramadol treated mice. All gene expression levels were normalized to GAPDH, n = 10. Data are expressed as means +- SEM, *p < 0.05 for control versus tramadol. ( g ) Immunohistochemistry staining images x100 (inset: x400) showing VEGF expression in cardiac muscle of control and tramadol treated mice. Arrows show the specific staining for the antibody. ( h ) Relative quantification of immunohistochemistry staining for VEGF in cardiac muscle of control and tramadol treated mice, n = 10. Data are expressed as means +- SEM, *p < 0.05 for control versus tramadol.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 2. hSTSG promotes strong recruitment of circulating cells compared to ADM. ( A ) Schematic of the parabiosis model ( n = 5 pairs per group). ( B ) Confocal microscopy of hSTSGs and ADM with overlying murine skin as well as sham tissue showing circulating GFP + cells and immunofluorescent staining for CD31. ( C ) Circulating GFP + cells and immunofluorescent staining for VEGF. ( D ) Flow cytometry analysis of circulating GFP + cells {gating on live [4',6-diamidino-2-phenylindole (DAPI)-negative] single cells}. Dotted line on histology images indicates the interface between murine skin and graft. White rectangles indicate the location of the magnified images (right). Scale bars, 200 mum in overview images (left) and sham image, 50 mum in magnified images (right), and 20 mum in magnified image showing VEGF- and GFP-expressing circulating cell. SSW, side scatter width.